Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TulmiSTAR-01
CTR20254907Phase 2Active
- Sponsor
- Novartis
- Start
- Apr 2026
- Modality
- Small Molecules, PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tulmimetostat, luxdegalutamide in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Novartis. Started Apr 2026; status: active.
02
Drugs
tulmimetostatluxdegalutamide
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on CTR20254907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254907.